To hear about similar clinical trials, please enter your email below
Trial Title:
Feasibility of Evaluating Gene Alteration Analysis Using Samples Obtained by EBUS-TBNA in Patients With Lung Cancer
NCT ID:
NCT01487603
Condition:
Lung Cancer
Conditions: Official terms:
Lung Neoplasms
Conditions: Keywords:
Patients
undiagnosed enlarged
lymph nodes
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Summary:
Lung cancer is the leading cause of death in the world. Overall 5-year survival rate is
fewer than 10% and the effectiveness of conventional chemotherapy is limited. The new
knowledge shows the correlation between genetic alteration and effective of chemotherapy.
Therefore non-surgical modalities to obtain tumor specimens for genetic alteration
analysis are particularly critical in lung cancer, since many patients have advanced
disease at the time of first presentation, and are therefore not eligible for radical
surgery. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
samples obtained during diagnosis of lung cancer can be used for molecular analysis that
will predict response to treatment and prognosis. In this study, we will detect specific
target molecules related to the effectiveness of treatment (surgery, chemotherapy,
radiotherapy) and prognosis in patients with lung cancer using EBUS-TBNA samples and its
combined with xenograft technology.
Criteria for eligibility:
Study pop:
Patients with lung cancer
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Age 18 years or older.
- Patients with confirmed or suspected lung cancer who require EBUS-TBNA as part of
their staging investigations of the mediastinum will be considered for the trial.
- Patients with undiagnosed enlarged lymph nodes in the mediastinum suspicious for
lung cancer in which a tissue diagnosis is required.
Exclusion Criteria:
- Patients who are deemed on clinical grounds not to be medically fit for a
bronchoscopy.
- Patients where there is a high clinical suspicion of lymphoma.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
University Health Network
Address:
City:
Toronto
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Judy McConnell
Phone:
416-581-7486
Start date:
October 2011
Completion date:
October 2025
Lead sponsor:
Agency:
University Health Network, Toronto
Agency class:
Other
Source:
University Health Network, Toronto
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT01487603
